  On August 31, 2007, the US Food and Drug Administration  (FDA) approved 

Somatuline depot (lanreotide acetate injection)

 60, 90, and 120 mg for  marketing in the United States.  Somatuline depot, manufactured by Tercica, Inc. (Brisbane, CA, 

), is indicated for the  long-term treatment of acromegaly in patients who have had an inadequate  response to surgery or radiotherapy, or for whom surgery or radiotherapy is not  an option. Somatuline depot will be available in a pre-filled syringe  eliminating the need for reconstitution. Somatuline depot is expected to launch  in the United States in the fourth quarter 2007.

News

On August 31, 2007, the US Food and Drug Administration (FDA) approved Somatuline depot (lanreotide) injection 60, 90, and 120 mg for marketing in the United States.